Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced this morning that its phase 2 trial enrollment and dosing for PEGPH20 has come to a halt, driving its stock price down more than 31% in pre-market trading. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $7.94 moved to $9.20 on last trade day and at the end of the day closed at $8.43. Company price to sales ratio in past twelve months was calculated as 16.31 and price to cash ratio as 16.01. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -30.39%.
Exact Sciences Corp. (NASDAQ:EXAS) Friday said it is offering 10 million shares in an underwritten public offering at a $12.75 per share price, and is expecting net proceeds of about $119.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses. EXACT Sciences Corporation (NASDAQ:EXAS) shares advanced 5.73% in last trading session and ended the day on $13.66. EXAS return on equity ratio is recorded as -35.60% and its return on assets is -33.00%. EXACT Sciences Corporation (NASDAQ:EXAS) yearly performance is 36.74%.
Berkeley Heights-based Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) announced Friday the pricing of its public offering of 2.857 million shares of common stock at a price of $3.50 per share. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) shares moved up 2.16% in last trading session and was closed at $3.79, while trading in range of $3.45 – $3.79. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) year to date (YTD) performance is -5.72%.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced yesterday that it will present data on the comparison of Cynviloq™ and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies.
Sorrento Therapeutics Inc. (NASDAQ:SRNE) weekly performance is -13.32%. On last trading day company shares ended up $11.26. Sorrento Therapeutics Inc. (NASDAQ:SRNE) distance from 50-day simple moving average (SMA50) is -5.00%. Analysts mean target price for the company is $23.00.